Search results
Results From The WOW.Com Content Network
The first-line treatment is generally given to patients as an initial antiretroviral therapy and is the cheapest of the stages of treatments. [1] The first-line antiretroviral drug treatment as recommended by the World Health Organization (WHO) involves TDF (tenofovir), 3TC (lamivudine) or FTC (emtricitabine), and EFV (efavirenz) or dolutegravir (DTG).
00:38. Lenacapavir’s current list price for use as HIV treatment is $3,450 per month. Gilead has not yet indicated whether it will set a different price for the drug’s use as PrEP. A company ...
HIV/AIDS was first detected in Canada in 1982. [1][2] In 2018, there were approximately 62,050 people living with HIV/AIDS in Canada. [3] It was estimated that 8,300 people were living with undiagnosed HIV in 2018. [3] Mortality has decreased due to medical advances against HIV/AIDS, especially highly active antiretroviral therapy (HAART).
Management of HIV/AIDS. The management of HIV/AIDS normally includes the use of multiple antiretroviral drugs as a strategy to control HIV infection. [1] There are several classes of antiretroviral agents that act on different stages of the HIV life-cycle. The use of multiple drugs that act on different viral targets is known as highly active ...
Treatment as prevention. Treatment as prevention (TasP) is a concept in public health that promotes treatment as a way to prevent and reduce the likelihood of HIV illness, death and transmission from an infected individual to others. Expanding access to earlier HIV diagnosis and treatment as a means to address the global epidemic by preventing ...
Lenacapavir was approved for medical treatment in the European Union in August 2022, [10] [12] in Canada in November 2022, [5] [6] and in the United States in December 2022. [9] [11] [13] [14] It is the first of a class of drugs called capsid inhibitors to be approved by the US Food and Drug Administration (FDA) for treating HIV/AIDS. [11] [15]
Pre-exposure prophylaxis for HIV prevention, commonly known as PrEP, is the use of antiviral drugs as a strategy for the prevention of HIV/AIDS by people that do not yet have HIV/AIDS. [1] PrEP is one of a number of HIV prevention strategies for people who are HIV negative but who have a higher risk of acquiring HIV, including sexually active ...
Raltegravir. Raltegravir, sold under the brand name Isentress, is an antiretroviral medication used, together with other medication, to treat HIV/AIDS. [5] It may also be used, as part of post exposure prophylaxis, to prevent HIV infection following potential exposure. [6] It is taken by mouth.